Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

NCT07079475 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: DZD6008
DRUG: Sunvozertinib
DRUG: Osimertinib

Sponsor

Dizal (Jiangsu) Pharmaceutical Co., Ltd.